Quebec News Tribune – Lifestyle
Author:
Oruka Therapeutics, Inc.
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
April 27, 2026
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
April 27, 2026
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
April 26, 2026
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 12, 2026